Delving into the Latest Updates on GEH121224 (18F) with Synapse

Overview

Basic Info

Drug Type

Diagnostic radiopharmaceuticals

Synonyms-

Target-

Mechanism

PET imaging(Positron-emission tomography enhancers)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

GE Healthcare, Inc.

Active Organization

GE Healthcare Holdings, Inc.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The study described in this protocol is a Phase 1, single center clinical trial to evaluate the safety and potential of [18F]GEH121224 as a PET radiotracer for the diagnostic imaging of HER2 positive breast cancer lesions. A group of 6 patients will be selected to perform a dosimetry study with [18F]GEH121224 followed by another group of 6 patients in a test-retest study. The results of this study will provide crucial information to guide the development of [18F]GEH121224 for the detection of HER2 status in advanced breast cancer patients. This study will use established methods for characterizing the radiation dosimetry, biodistribution and basic pharmacokinetics of a radiotracer.

Start Date01 Jan 2025

Sponsor / Collaborator

GE Healthcare Holdings, Inc.

[+1]

100 Clinical Results associated with GEH121224 (18F)

Login to view more data

100 Translational Medicine associated with GEH121224 (18F)

Login to view more data

100 Patents (Medical) associated with GEH121224 (18F)

Login to view more data

100 Deals associated with GEH121224 (18F)

Login to view more data